Drugs / cAD3-Sudan Ebolavirus Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06036602 | Jul 2024 → Nov 2025 | Ebola hemorrhagic fever | Albert B. Sabin Vaccine Institute | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cAD3-Sudan Ebolavirus Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06036602 ↗ |
| Known as | cAd3-EBO S | “The recombinant chimpanzee adenovirus Type 3-vectored Sudan Ebolavirus vaccine, (cAd3-EBO S) is composed of a cAd3 vector that expresses wild type glycoprotein (WT GP) from the...” NCT06036602 ↗ |
| Modality | Vaccine | “recombinant chimpanzee adenovirus Type 3-vectored Sudan Ebolavirus vaccine” NCT06036602 ↗ |
| Route | Intramuscular | “administered intramuscularly (IM)” NCT06036602 ↗ |